| 前收盘价格 | 7.37 |
| 收盘价格 | 7.36 |
| 成交量 | 1,266,044 |
| 平均成交量 (3个月) | 2,080,549 |
| 市值 | 936,899,648 |
| 价格/销量 (P/S) | 1.43 |
| 股市价格/股市净资产 (P/B) | 1.10 |
| 52周波幅 | |
| 利润日期 | 28 Jul 2025 |
| 营业毛利率 | -11.54% |
| 营业利益率 (TTM) | -16.56% |
| 稀释每股收益 (EPS TTM) | -0.610 |
| 季度收入增长率 (YOY) | 7.50% |
| 总债务/股东权益 (D/E MRQ) | 68.08% |
| 流动比率 (MRQ) | 2.05 |
| 营业现金流 (OCF TTM) | 7.61 M |
| 杠杆自由现金流 (LFCF TTM) | -2.21 M |
| 资产报酬率 (ROA TTM) | -2.75% |
| 股东权益报酬率 (ROE TTM) | -8.56% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | NeoGenomics, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.90 |
|
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.19% |
| 机构持股比例 | 100.72% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 12.00 (Piper Sandler, 64.84%) | 购买 |
| 中 | 10.00 (37.36%) | |
| 低 | 8.50 (Needham, 16.76%) | 购买 |
| 平均值 | 9.90 (35.99%) | |
| 总计 | 3 购买, 2 保留 | |
| 平均价格@调整类型 | 6.87 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 06 May 2025 | 12.00 (64.84%) | 购买 | 7.69 |
| Morgan Stanley | 01 May 2025 | 10.00 (37.36%) | 保留 | 7.26 |
| Goldman Sachs | 30 Apr 2025 | 10.00 (37.36%) | 购买 | 6.40 |
| 17 Apr 2025 | 15.00 (106.04%) | 购买 | 9.55 | |
| Leerink Partners | 30 Apr 2025 | 9.00 (23.63%) | 保留 | 6.40 |
| Needham | 29 Apr 2025 | 8.50 (16.76%) | 购买 | 6.58 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FLOEGEL ELIZABETH | - | - | 0 | 0 |
| GUNN NEIL | - | - | 0 | 0 |
| HANNAH ALISON L. | 7.28 | - | 12,254 | 89,209 |
| KANOVSKY STEPHEN M | - | - | 0 | 0 |
| KELLY MICHAEL AARON | - | - | 0 | 0 |
| PEREZ DAVID BRIAN | - | - | 0 | 0 |
| TETRAULT LYNN A. | - | - | 0 | 0 |
| WILLIAMS FELICIA | - | - | 0 | 0 |
| ZOOK ANTHONY P. | - | 7.28 | -3,424 | -24,927 |
| 累积净数量 | 8,830 | |||
| 累积净值 ($) | 64,282 | |||
| 累积平均购买 ($) | 7.28 | |||
| 累积平均卖出 ($) | 7.28 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PEREZ DAVID BRIAN | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| ZOOK ANTHONY P. | 职员 | 01 Jun 2025 | 处理 (-) | 3,424 | 7.28 | 24,927 |
| ZOOK ANTHONY P. | 职员 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| GUNN NEIL | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| FLOEGEL ELIZABETH | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| HANNAH ALISON L. | 董事 | 01 Jun 2025 | 获得 (+) | 12,254 | 7.28 | 89,209 |
| TETRAULT LYNN A. | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| KELLY MICHAEL AARON | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| KANOVSKY STEPHEN M | 董事 | 01 Jun 2025 | 执行期权 | 12,254 | - | - |
| WILLIAMS FELICIA | 董事 | 01 Jun 2025 | 执行期权 | 7,160 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合